← All candidates
13 insider filings on record.
26 filings on record.
ALLOAllogene Therapeutics, Inc.
NasdaqGS · Healthcare · $583.88M
$1.69
-1.74% today
13 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 10 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$583.88M
Float
262.4M
76% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
125.8
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
8 more transactions on Pro →Context
Wall St
$9.00 avg target
+432.5% vs today · 9 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q2 '26−$0.13 act+$0.02
Q1 '26−$0.18 act+$0.00
Q4 '25−$0.17 act+$0.05
Q3 '25−$0.19 act+$0.04
Coverage
Allogene (ALLO) Q2 2026 Earnings Call TranscriptMotley Fool · 4w agoIs Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?Zacks · 08-17Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D CostsZacks · 08-13Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC SaysMT Newswires · 08-13
The file stays open
26 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice